Orforglipron

Orforglipron (brand name Foundayo) is a once-daily oral medication that activates the glucagon-like peptide-1 (GLP-1) receptor, the same target engaged by injectable medicines such as semaglutide and tirzepatide ². GLP-1 is a gut hormone released after eating that helps control blood sugar and appetite, and orforglipron reproduces that signal ³⁶. What sets it apart is its chemistry: it is a small molecule rather than a peptide, so it is taken as a pill, and it has no fasting or water-timing rules ⁴.

Eli Lilly developed the compound (development code LY3502970) and published its receptor-bound structure in 2020 ³. A phase 2 trial in adults with obesity showed dose-dependent weight loss of about 9.4% to 14.7% over 36 weeks depending on dose ⁹, and a phase 2 trial in type 2 diabetes showed meaningful reductions in HbA1c, a measure of average blood sugar ¹⁰. The confirmatory phase 3 programs, named ATTAIN for weight management and ACHIEVE for type 2 diabetes, enrolled more than 11,000 participants across seven trials and reported between 2025 and 2026 ¹¹.

The US FDA approved orforglipron in April 2026 for long-term weight management in adults with obesity, or overweight plus at least one weight-related condition, as an add-on to a reduced-calorie diet and increased physical activity ². It is the second oral GLP-1 receptor agonist cleared in the US for this use and the first that is a small molecule ². Research is also exploring maintenance of weight loss after switching from injectable GLP-1 drugs ¹⁶, obstructive sleep apnea ²⁹, and high blood pressure ⁵⁴. Renal safety data from phase 3 trials showed stable eGFR and no significant renal toxicity, but those trials were not designed or powered to evaluate renal outcomes and underrepresented people with advanced chronic kidney disease. No completed cardiovascular outcomes trial exists for orforglipron; cardiovascular benefit is currently inferred only from risk-factor changes and modeling, not from MACE outcome data.

After a meal, the gut releases glucagon-like peptide-1 (GLP-1), a hormone that tells the pancreas to release insulin when blood sugar is high, suppresses glucagon, slows stomach emptying, and sends fullness signals to the brain ³⁶. Orforglipron binds to the GLP-1 receptor and switches on the same chain of events ³.

It is described as a G-protein-biased partial agonist ⁴. In plain terms, the receptor's main switch is a pathway that raises a messenger molecule called cyclic AMP (cAMP), and orforglipron activates that pathway well. At the same time it barely recruits beta-arrestin, a protein that normally dampens the signal and pulls the receptor inside the cell ⁴. Scientists reason that this bias may reduce the desensitization, the fading response to repeated stimulation, that can limit other drugs, although the clinical importance remains to be established ⁴.

Structural studies show the molecule docks in a pocket on the upper, outer part of the human GLP-1 receptor, a site peptide drugs do not occupy, and it binds tightly (Ki around 1 nM) ³. It is highly selective for the human receptor and barely active at the rodent version, which is why animal work uses mice engineered to carry the human receptor ⁴. In silico modeling suggests rare natural receptor variants (G168S, R131Q) change how the molecule anchors, a potential source of response differences that has not been validated in patients ³¹.

Downstream measurements match the receptor picture. In type 2 diabetes trials, doses of 12 mg or more raised beta-cell function markers (HOMA-B) by up to 123–132% and reduced insulin resistance (HOMA-IR) by up to 16–23% ³². Phase 2 biomarker analyses found reductions in systolic blood pressure, LDL cholesterol, triglycerides, apoB, and the inflammatory marker hsCRP ²⁴.

Weight loss

In ATTAIN-1, a 72-week placebo-controlled trial in 3,127 adults with obesity but not diabetes, mean weight change was −7.5% (6 mg), −8.4% (12 mg), and −11.2% (36 mg) versus −2.1% with placebo ¹¹. At 36 mg, 54.6% of participants lost at least 10% of body weight, 36.0% at least 15%, and 18.4% at least 20% ¹¹. In ATTAIN-2, which enrolled people with both obesity and type 2 diabetes, the same doses produced −5.1%, −7.0%, and −9.6% versus −2.5% placebo ¹. Adults 65 and older lost a comparable amount ¹⁷.

Blood sugar in type 2 diabetes

In ACHIEVE-1 (early diabetes, no glucose-lowering drugs at entry), 40 weeks of 3/12/36 mg lowered HbA1c by 1.24, 1.47, and 1.48 percentage points versus 0.41 on placebo, alongside weight loss up to 7.6% ¹². Against the SGLT2 inhibitor dapagliflozin, all orforglipron doses were superior for HbA1c ¹³. In head-to-head ACHIEVE-3, 12 mg and 36 mg beat oral semaglutide 7/14 mg on both HbA1c and weight ¹⁴. Added to titrated insulin glargine, 36 mg cut HbA1c by 1.82 points and weight by 5.4% without increasing clinically significant hypoglycemia ¹⁵.

Maintenance after injectables

In ATTAIN-MAINTAIN, people who had responded to injectable tirzepatide or semaglutide and then switched to orforglipron kept 74.7% and 79.3% of their achieved weight loss at week 52, versus 49.2% and 37.6% for those switched to placebo ¹⁶.

Cardiometabolic markers

Across trials, systolic blood pressure, LDL cholesterol, triglycerides, apoB, and hsCRP fell meaningfully versus placebo ²⁴, and post hoc risk modeling of ATTAIN-1 estimated large relative reductions in predicted 10-year type 2 diabetes and cardiovascular risk ²⁵. Heart rate rises modestly, by about 4 to 5 beats per minute on average ¹⁴.

Preclinical leads

In human cell lines, orforglipron protected neurons against excitotoxic and oxidative damage and reduced inflammatory signals from microglia ⁷. In mice carrying the human GLP-1 receptor, it attenuated experimentally induced aortic aneurysm formation ⁸. These findings are promising but remain a long way from clinical proof ⁷.

Where it sits versus other drugs

A 262-trial network meta-analysis estimated about 9.9% weight loss versus lifestyle change alone at one year, placing orforglipron in the same neighborhood as oral semaglutide and below tirzepatide ²⁷. A dose-comparison meta-analysis found 36 mg consistently outperformed 12 mg on weight, BMI, HbA1c, waist circumference, triglycerides, and systolic blood pressure, with similar adverse events ²⁶.

Orforglipron protocols use fixed, once-daily oral doses. No published protocol adjusts the dose by body weight, and trial populations had BMI values of 23 or higher per ACHIEVE eligibility; no upper BMI limit was reported ¹. The pivotal phase 3 programs evaluated maintenance doses of 3, 6, 12, and 36 mg, with capsule strengths from 1 to 36 mg and tablet strengths from 0.8 to 17.2 mg; each tablet strength is bioequivalent to its capsule counterpart ²².

Every phase 3 protocol began with a standardized dose-escalation phase, because the gastrointestinal side effects that dominate the side-effect profile concentrate during escalation ¹¹. The exact step schedule was not published in detail: a phase 1 food-effect study escalated weekly from 2 mg to 16 mg ¹⁹, and a Chinese titration cohort reached 12 mg by week 16 and 36 mg by week 24 ³⁸. Practitioner consensus converged on a slower pattern: begin at 2.5–3 mg and advance in roughly doubling steps every 2–4 weeks toward 17.2 mg (the 36 mg-equivalent tablet), holding at any step where nausea persists rather than advancing.

No food or water rules apply. Food lowers exposure by about 18–24% without changing the elimination half-life, a difference judged not clinically meaningful, so the dose can be taken with or without food ¹⁹. This is a practical contrast with oral semaglutide, which requires fasting and timed water intake ¹⁴.

Duration is chronic. The weight-management approval is for long-term use, trials ran 40–104 weeks ¹, and no cycling protocol exists in the literature. Regain after stopping is the expected pattern: the placebo arm of ATTAIN-MAINTAIN retained only about 38–49% of prior weight loss over a year, versus roughly three-quarters with orforglipron ¹⁶.

Monitoring during protocols centers on GI tolerance at each escalation step ¹¹, resting pulse (which rises a few beats per minute) ¹⁴, and periodic liver, lipid, and HbA1c panels ²³. Because orforglipron is metabolized mainly by the liver through CYP3A4, strong CYP3A4 inhibitors or inducers change exposure and may require dose attention ²¹.

Drugs that raise or lower orforglipron levels

Orforglipron is carried by enzymes and transporters including CYP3A4, OATP1B, and P-glycoprotein ²¹. In phase 1 studies, the antibiotic clarithromycin (a strong CYP3A4 inhibitor) and the immunosuppressant cyclosporine raised orforglipron exposure substantially, while the seizure drug carbamazepine (a CYP3A4 inducer) lowered it; the P-glycoprotein inhibitor quinidine had little effect ²¹. Expect more GI side effects if exposure rises, and potentially reduced effect with strong inducers ²¹. By analogy, grapefruit would be expected to raise exposure and St. John's wort to lower it, though neither was tested directly ²¹.

Effects on other drugs

Orforglipron did not meaningfully change levels of midazolam, digoxin, or atorvastatin. It weakly raised rosuvastatin exposure through BCRP inhibition, which does not require routine statin dose changes ²¹.

Glucose-lowering combinations

Adding orforglipron to titrated insulin glargine lowered HbA1c without increasing clinically significant hypoglycemia, though rare severe events occurred ¹⁵. With background oral glucose-lowering drugs, about 2% of participants in the Japanese long-term trial had blood glucose below 54 mg/dL ¹⁸. As glycemia improves, insulin or sulfonylurea doses often need reduction ¹⁵.

Gastric-emptying delay

GLP-1 receptor activation slows stomach emptying, an effect that is strongest early in treatment ³⁶. Formal orforglipron studies have not tested whether this changes absorption of drugs with narrow safety windows (levothyroxine, oral contraceptives, warfarin); class experience suggests the effect fades with ongoing dosing ³⁶.

Cardiovascular drugs

Systolic blood pressure falls and heart rate rises during treatment ¹⁴. Antihypertensive doses may need downward adjustment as weight falls, and the heart-rate rise matters for people taking stimulants or rhythm drugs ⁴³.

What is studied

Orforglipron's phase 3 diabetes program combined it with metformin, with dapagliflozin as a comparator background, and with titrated insulin glargine; all were safe combinations, with no increase in clinically significant hypoglycemia on insulin ¹³. The most common background therapy in the ACHIEVE trials was metformin ¹³.

Sequential use after injectables

The best-studied combination strategy is sequential rather than simultaneous. In ATTAIN-MAINTAIN, people coming off injectable tirzepatide or semaglutide who switched to orforglipron preserved about three-quarters of their weight loss at one year, versus roughly 40–50% on placebo ¹⁶. Community protocol is to start orforglipron around the day the next weekly injection would be due, sometimes with a short overlap for high-dose injectable users to blunt GI symptoms.

Avoid stacking with other GLP-1 receptor drugs

Adding semaglutide, liraglutide, or tirzepatide to orforglipron means two drugs hitting the same receptor with no expected added benefit and compounded nausea. Practitioner consensus is against concurrent GLP-1 stacking.

Unstudied combinations

Amylin analogs such as cagrilintide or pramlintide would add further gastric slowing and satiety, raising nausea risk with no safety data. Multi-receptor agonists (such as retatrutide) and weight-related peptides (AOD-9604, tesamorelin) have no interaction data with orforglipron, so their combination is unsupported.

Supplements

Berberine and capsicum/capsaicin were compared with orforglipron in computational and animal models, but combined use in humans has not been studied and could add glucose-lowering effect, especially with insulin or sulfonylureas ⁵⁰. Statin co-therapy carries low interaction risk aside from a minor rosuvastatin increase ²¹.

Approval

The US FDA approved orforglipron as Foundayo in April 2026, its first global approval, for long-term weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity ². The application moved through the FDA's National Priority Voucher fast-track program ⁵¹. It is the second oral GLP-1 receptor agonist cleared in the US for this use and the first small-molecule one ⁵².

Other regulators

The UK's MHRA has approved the weight-loss pill ⁵³. Submissions are under review in the EU (weight management and type 2 diabetes), Japan (weight management), and Canada (type 2 diabetes) ². Type 2 diabetes approval is therefore pending in several regions, and use for diabetes is off-label in the meantime ².

Investigational indications

Phase 3 programs are running for obstructive sleep apnea ²⁹, hypertension ⁵⁴, stress urinary incontinence, osteoarthritis pain, and peripheral arterial disease ². None of these is approved yet.

Maintenance transition

Using orforglipron to sustain weight loss after injectable GLP-1 drugs is supported by the ATTAIN-MAINTAIN phase 3b trial but remains an off-label pattern not yet reflected in the label ¹⁶.

Controlled-substance and compounding status

No scheduling designation appears in the literature; GLP-1 receptor agonists are not controlled substances. US compounding pharmacies (503A/503B) may compound only for patient-specific needs or during FDA-declared shortages, and no orforglipron shortage is documented.

Anti-doping

No WADA or USADA classification for orforglipron appears in the literature. It is not an anabolic agent, a listed peptide hormone, a stimulant, or a masking agent by category, and GLP-1 receptor agonists have not appeared on the WADA Prohibited List in the covered material. Athletes should check the current Prohibited List each cycle.

Gastrointestinal events dominate

Nausea, vomiting, diarrhea, and decreased appetite are the most common side effects, are mostly mild to moderate, and cluster in the first weeks of dose escalation ¹¹. In the ACHIEVE diabetes trials, GI events occurred in roughly 47–59% of participants on orforglipron versus 12% on dapagliflozin ¹³ and 37–45% on oral semaglutide ¹⁴. A network meta-analysis put GI event risk roughly three-fold above lifestyle control and discontinuation risk up to four-fold higher ²⁷. Fatigue is also more common, at roughly 100 extra cases per 1,000 per year ²⁷.

Discontinuation

Rates rise with dose: 14% at 36 mg versus 5% at 3 mg in the 52-week Japanese trial ¹⁸; 15–20% versus 6% for dapagliflozin ¹³; 9–10% versus 4–5% for oral semaglutide ¹⁴; and up to about 10% versus 2.7% placebo in obesity trials ¹¹. Slow, tolerance-based escalation is the standard mitigation.

Heart rate and blood pressure

Pulse rises about 3.7–4.7 beats per minute in head-to-head trials, higher than oral semaglutide's 1.0–1.5 ¹⁴; meta-analytic estimates average around 6 beats per minute ⁴³. Systolic blood pressure falls modestly ²⁴.

Hypoglycemia

Rare with orforglipron alone; no severe episodes occurred in the early-diabetes monotherapy trial ¹². Added to insulin glargine, it did not increase clinically significant hypoglycemia ¹⁵. Level-2 events (glucose under 54 mg/dL) occurred in about 2% of participants on background oral agents ¹⁸. Risk concentrates with insulin or sulfonylureas.

Liver

A pooled analysis of 11,220 phase 3 participants followed up to 104 weeks found no drug-induced liver injury and no Hy's Law cases; on average, liver enzymes fell as weight was lost ²³.

Ocular caution

There are no direct orforglipron NAION data, but its high oral exposure places it in a concentration band flagged for class-level surveillance ³⁰. A diabetic-retinopathy signal appeared in one diabetes trial despite excluding baseline retinopathy ³⁰; rapid HbA1c drops are a recognized driver of retinopathy worsening in the class ³⁰.

Less common and theoretical

Meta-analyses have not found a significant pancreatitis excess ⁴¹; gallbladder problems are a recognized class concern ³⁶; and class literature mentions skin changes and hair loss ⁴⁴. The standard class contraindication applies to people with medullary thyroid carcinoma or MEN2 ³⁶. Pregnancy use is not studied, and class practice is to stop before conception ³⁶.

Monitoring

Trial-based guidance includes baseline liver enzymes, HbA1c, lipids, blood pressure, and resting pulse ²³; a dilated retinal exam in people with diabetes, especially with existing retinopathy ³⁰; GI tolerance checks at each escalation step ¹⁴; and a repeat liver panel a few months after reaching the maintenance dose ²³.